Hematological Malignancies Market, Global Outlook and Forecast 2022-2028

March 2022 | 64 pages | ID: H180664A788AEN
Market Monitor Global

Abstracts

Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system.

This report contains market size and forecasts of Hematological Malignancies in Global, including the following market information:

Global Hematological Malignancies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Hematological Malignancies market was valued at 30590 million in 2021 and is projected to reach US$ 40570 million by 2028, at a CAGR of 4.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Leukemia Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hematological Malignancies include AbbVie, Bristol-Myers Squibb, Celgene, Roche, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer and Teva Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematological Malignancies companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hematological Malignancies Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Hematological Malignancies Market Segment Percentages, by Type, 2021 (%)

• Leukemia
• Lymphoma
• Myeloma
• Others

Global Hematological Malignancies Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Hematological Malignancies Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Others

Global Hematological Malignancies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Hematological Malignancies Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hematological Malignancies revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Hematological Malignancies revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AbbVie
• Bristol-Myers Squibb
• Celgene
• Roche
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
• Pfizer
• Teva Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Hematological Malignancies Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Hematological Malignancies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL HEMATOLOGICAL MALIGNANCIES OVERALL MARKET SIZE

2.1 Global Hematological Malignancies Market Size: 2021 VS 2028
2.2 Global Hematological Malignancies Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Hematological Malignancies Players in Global Market
3.2 Top Global Hematological Malignancies Companies Ranked by Revenue
3.3 Global Hematological Malignancies Revenue by Companies
3.4 Top 3 and Top 5 Hematological Malignancies Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hematological Malignancies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancies Players in Global Market
  3.6.1 List of Global Tier 1 Hematological Malignancies Companies
  3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancies Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Hematological Malignancies Market Size Markets, 2021 & 2028
  4.1.2 Leukemia
  4.1.3 Lymphoma
  4.1.4 Myeloma
  4.1.5 Others
4.2 By Type - Global Hematological Malignancies Revenue & Forecasts
  4.2.1 By Type - Global Hematological Malignancies Revenue, 2017-2022
  4.2.2 By Type - Global Hematological Malignancies Revenue, 2023-2028
  4.2.3 By Type - Global Hematological Malignancies Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Hematological Malignancies Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinics
  5.1.4 Others
5.2 By Application - Global Hematological Malignancies Revenue & Forecasts
  5.2.1 By Application - Global Hematological Malignancies Revenue, 2017-2022
  5.2.2 By Application - Global Hematological Malignancies Revenue, 2023-2028
  5.2.3 By Application - Global Hematological Malignancies Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hematological Malignancies Market Size, 2021 & 2028
6.2 By Region - Global Hematological Malignancies Revenue & Forecasts
  6.2.1 By Region - Global Hematological Malignancies Revenue, 2017-2022
  6.2.2 By Region - Global Hematological Malignancies Revenue, 2023-2028
  6.2.3 By Region - Global Hematological Malignancies Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Hematological Malignancies Revenue, 2017-2028
  6.3.2 US Hematological Malignancies Market Size, 2017-2028
  6.3.3 Canada Hematological Malignancies Market Size, 2017-2028
  6.3.4 Mexico Hematological Malignancies Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Hematological Malignancies Revenue, 2017-2028
  6.4.2 Germany Hematological Malignancies Market Size, 2017-2028
  6.4.3 France Hematological Malignancies Market Size, 2017-2028
  6.4.4 U.K. Hematological Malignancies Market Size, 2017-2028
  6.4.5 Italy Hematological Malignancies Market Size, 2017-2028
  6.4.6 Russia Hematological Malignancies Market Size, 2017-2028
  6.4.7 Nordic Countries Hematological Malignancies Market Size, 2017-2028
  6.4.8 Benelux Hematological Malignancies Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Hematological Malignancies Revenue, 2017-2028
  6.5.2 China Hematological Malignancies Market Size, 2017-2028
  6.5.3 Japan Hematological Malignancies Market Size, 2017-2028
  6.5.4 South Korea Hematological Malignancies Market Size, 2017-2028
  6.5.5 Southeast Asia Hematological Malignancies Market Size, 2017-2028
  6.5.6 India Hematological Malignancies Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Hematological Malignancies Revenue, 2017-2028
  6.6.2 Brazil Hematological Malignancies Market Size, 2017-2028
  6.6.3 Argentina Hematological Malignancies Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Hematological Malignancies Revenue, 2017-2028
  6.7.2 Turkey Hematological Malignancies Market Size, 2017-2028
  6.7.3 Israel Hematological Malignancies Market Size, 2017-2028
  6.7.4 Saudi Arabia Hematological Malignancies Market Size, 2017-2028
  6.7.5 UAE Hematological Malignancies Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie
  7.1.1 AbbVie Corporate Summary
  7.1.2 AbbVie Business Overview
  7.1.3 AbbVie Hematological Malignancies Major Product Offerings
  7.1.4 AbbVie Hematological Malignancies Revenue in Global Market (2017-2022)
  7.1.5 AbbVie Key News
7.2 Bristol-Myers Squibb
  7.2.1 Bristol-Myers Squibb Corporate Summary
  7.2.2 Bristol-Myers Squibb Business Overview
  7.2.3 Bristol-Myers Squibb Hematological Malignancies Major Product Offerings
  7.2.4 Bristol-Myers Squibb Hematological Malignancies Revenue in Global Market (2017-2022)
  7.2.5 Bristol-Myers Squibb Key News
7.3 Celgene
  7.3.1 Celgene Corporate Summary
  7.3.2 Celgene Business Overview
  7.3.3 Celgene Hematological Malignancies Major Product Offerings
  7.3.4 Celgene Hematological Malignancies Revenue in Global Market (2017-2022)
  7.3.5 Celgene Key News
7.4 Roche
  7.4.1 Roche Corporate Summary
  7.4.2 Roche Business Overview
  7.4.3 Roche Hematological Malignancies Major Product Offerings
  7.4.4 Roche Hematological Malignancies Revenue in Global Market (2017-2022)
  7.4.5 Roche Key News
7.5 GlaxoSmithKline
  7.5.1 GlaxoSmithKline Corporate Summary
  7.5.2 GlaxoSmithKline Business Overview
  7.5.3 GlaxoSmithKline Hematological Malignancies Major Product Offerings
  7.5.4 GlaxoSmithKline Hematological Malignancies Revenue in Global Market (2017-2022)
  7.5.5 GlaxoSmithKline Key News
7.6 Johnson & Johnson
  7.6.1 Johnson & Johnson Corporate Summary
  7.6.2 Johnson & Johnson Business Overview
  7.6.3 Johnson & Johnson Hematological Malignancies Major Product Offerings
  7.6.4 Johnson & Johnson Hematological Malignancies Revenue in Global Market (2017-2022)
  7.6.5 Johnson & Johnson Key News
7.7 Novartis
  7.7.1 Novartis Corporate Summary
  7.7.2 Novartis Business Overview
  7.7.3 Novartis Hematological Malignancies Major Product Offerings
  7.7.4 Novartis Hematological Malignancies Revenue in Global Market (2017-2022)
  7.7.5 Novartis Key News
7.8 Pfizer
  7.8.1 Pfizer Corporate Summary
  7.8.2 Pfizer Business Overview
  7.8.3 Pfizer Hematological Malignancies Major Product Offerings
  7.8.4 Pfizer Hematological Malignancies Revenue in Global Market (2017-2022)
  7.8.5 Pfizer Key News
7.9 Teva Pharmaceutical
  7.9.1 Teva Pharmaceutical Corporate Summary
  7.9.2 Teva Pharmaceutical Business Overview
  7.9.3 Teva Pharmaceutical Hematological Malignancies Major Product Offerings
  7.9.4 Teva Pharmaceutical Hematological Malignancies Revenue in Global Market (2017-2022)
  7.9.5 Teva Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hematological Malignancies Market Opportunities & Trends in Global Market
Table 2. Hematological Malignancies Market Drivers in Global Market
Table 3. Hematological Malignancies Market Restraints in Global Market
Table 4. Key Players of Hematological Malignancies in Global Market
Table 5. Top Hematological Malignancies Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hematological Malignancies Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hematological Malignancies Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hematological Malignancies Product Type
Table 9. List of Global Tier 1 Hematological Malignancies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Malignancies Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Hematological Malignancies Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hematological Malignancies Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hematological Malignancies Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Hematological Malignancies Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hematological Malignancies Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hematological Malignancies Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Hematological Malignancies Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hematological Malignancies Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hematological Malignancies Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hematological Malignancies Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hematological Malignancies Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hematological Malignancies Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hematological Malignancies Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hematological Malignancies Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hematological Malignancies Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hematological Malignancies Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hematological Malignancies Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hematological Malignancies Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hematological Malignancies Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Hematological Malignancies Product Offerings
Table 32. AbbVie Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb Hematological Malignancies Product Offerings
Table 35. Bristol-Myers Squibb Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 36. Celgene Corporate Summary
Table 37. Celgene Hematological Malignancies Product Offerings
Table 38. Celgene Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 39. Roche Corporate Summary
Table 40. Roche Hematological Malignancies Product Offerings
Table 41. Roche Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline Corporate Summary
Table 43. GlaxoSmithKline Hematological Malignancies Product Offerings
Table 44. GlaxoSmithKline Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 45. Johnson & Johnson Corporate Summary
Table 46. Johnson & Johnson Hematological Malignancies Product Offerings
Table 47. Johnson & Johnson Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis Hematological Malignancies Product Offerings
Table 50. Novartis Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer Corporate Summary
Table 52. Pfizer Hematological Malignancies Product Offerings
Table 53. Pfizer Hematological Malignancies Revenue (US$, Mn), (2017-2022)
Table 54. Teva Pharmaceutical Corporate Summary
Table 55. Teva Pharmaceutical Hematological Malignancies Product Offerings
Table 56. Teva Pharmaceutical Hematological Malignancies Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Hematological Malignancies Segment by Type in 2021
Figure 2. Hematological Malignancies Segment by Application in 2021
Figure 3. Global Hematological Malignancies Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hematological Malignancies Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hematological Malignancies Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hematological Malignancies Revenue in 2021
Figure 8. By Type - Global Hematological Malignancies Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hematological Malignancies Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hematological Malignancies Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hematological Malignancies Revenue Market Share, 2017-2028
Figure 12. US Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hematological Malignancies Revenue Market Share, 2017-2028
Figure 16. Germany Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 17. France Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hematological Malignancies Revenue Market Share, 2017-2028
Figure 24. China Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 28. India Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hematological Malignancies Revenue Market Share, 2017-2028
Figure 30. Brazil Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hematological Malignancies Revenue Market Share, 2017-2028
Figure 33. Turkey Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hematological Malignancies Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Celgene Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Roche Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Johnson & Johnson Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Teva Pharmaceutical Hematological Malignancies Revenue Year Over Year Growth (US$, Mn) & (2017-2022)